Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment slowed the fatal disease in a late-stage study.
Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment slowed the fatal disease in a late-stage study.
Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment appeared to slow the fatal disease's progress in a late-stage study
The drug significantly improved memory and other factors in patients when compared to a placebo, and more details about the study will be released in November.
Shares of Biogen and other drugmakers researching Alzheimer's disease soared early Wednesday after Japan's Eisai Co. said its potential treatment slowed the fatal disease in a late-stage study.